Table 2.
Baseline characteristics
| Ferric carboxymaltose (n = 836) | Iron isomaltoside‐1000 (n = 496) | |
|---|---|---|
| Age (year) (median, IQR) | 50.2 (34.1–73.6) | 53.2 (36.0–74.4) |
| Sex | ||
| Female | 612 (73.2%) | 369 (74.4%) |
| Male | 224 (26.8%) | 127 (25.6%) |
| Departments | ||
| Gastroenterology | 231 (27.6%) | 223 (44.9%) |
| Gynaecology | 155 (18.5%) | 34 (6.9%) |
| Internal Medicine | 259 (31.0%) | 188 (37.9%) |
| Other a | 191 (22.8%) | 51 (10.3%) |
| Presence of a comorbidity b | ||
| Gastrointestinal | 77 (9.2%) | 82 (16.5%) |
| Pulmonary | 32 (3.8%) | 37 (7.5%) |
| Dermatological | 30 (3.6%) | 15 (3.0%) |
| Rheumatological | 24 (2.9%) | 15 (3.0%) |
| Other c | 7 (0.84%) | 5 (1.0%) |
IQR, inter‐quartile range
a
Other includes cardiology, surgery, urology, dermatology, rheumatology, pediatrics, and ophthalmology, and the care hotel located near the hospital
b
Comorbidity: registered comorbidities at every administration of intravenous iron. Every comorbidity is counted separately
c
Other includes immunological and haematological comorbidities